Guo Jian-Jie, Li Xiu-Juan, Wan Jing-Jing
Department of Ophthalmology, the First Affiliated Hospital of Zhengzhou University, Zhengzhou 450000, Henan Province, China.
Int J Ophthalmol. 2023 Jun 18;16(6):921-927. doi: 10.18240/ijo.2023.06.14. eCollection 2023.
To analyze the efficacy and safety of subthreshold micropulse laser (SML) in the treatment of acute central serous chorioretinopathy (CSC).
This is a retrospective case analysis study. Totally 58 eyes of 58 patients were enrolled, and they were divided into different groups. And 39 patients were treated with SML (SML group) and 19 patients were only observed (observation group). The follow-up period was 3mo after diagnosis. The best corrected visual acuity (BCVA), central retinal thickness (CRT), superficial retinal vascular density (SRVD), deep retinal vascular density (DRVD), the superficial and deep foveal avascular zone (FAZ) area, retinal light sensitivity (RLS), perfusion area of choroidal capillary layer (CCL), subfoveal choroidal thickness (SFCT) and fundus autofluorescence (FAF) were investigated.
The BCVA, CRT, SRVD, DRVD, the superficial and deep FAZ area, RLS, SFCT of SML group were significantly improved at 3mo (all <0.05). In the observation group, only CRT, DRVD and SFCT were improved (all <0.05). Other research items in the observation group were not significantly different from baseline (all >0.05). At the last follow-up, the BCVA and RLS in the SML group were better than those in the observation group, and CRT was lower, SRVD and DRVD, perfusion area of CCL were larger (all <0.05). On FAF, no change of treatment spots was found after treatment. No structural laser damage was observed on optical coherence tomography (OCT) and optical coherence tomography angiography (OCTA), and no choroidal neovascularization was observed.
SML treatment of acute CSC can improve BCVA, RLS, and perfusion area of CCL, reduce CRT, increase SRVD and DRVD, and is safe.
分析阈下微脉冲激光(SML)治疗急性中心性浆液性脉络膜视网膜病变(CSC)的疗效和安全性。
这是一项回顾性病例分析研究。共纳入58例患者的58只眼,将其分为不同组。39例患者接受SML治疗(SML组),19例患者仅进行观察(观察组)。诊断后随访3个月。观察最佳矫正视力(BCVA)、视网膜中央厚度(CRT)、视网膜浅层血管密度(SRVD)、视网膜深层血管密度(DRVD)、浅层和深层黄斑无血管区(FAZ)面积、视网膜光敏感度(RLS)、脉络膜毛细血管层灌注面积(CCL)、黄斑下脉络膜厚度(SFCT)和眼底自发荧光(FAF)。
SML组在3个月时BCVA、CRT、SRVD、DRVD、浅层和深层FAZ面积、RLS、SFCT均有显著改善(均P<0.05)。观察组仅CRT、DRVD和SFCT有所改善(均P<0.05)。观察组其他研究指标与基线相比无显著差异(均P>0.05)。末次随访时,SML组的BCVA和RLS优于观察组,CRT较低,SRVD、DRVD、CCL灌注面积较大(均P<0.05)。FAF方面,治疗后治疗部位未发现变化。光学相干断层扫描(OCT)和光学相干断层扫描血管造影(OCTA)未观察到结构性激光损伤,也未观察到脉络膜新生血管。
SML治疗急性CSC可改善BCVA、RLS和CCL灌注面积,降低CRT,增加SRVD和DRVD,且安全。